MRK is trading near fair value. No urgent action needed.
QuantHub Research: Investment Thesis
Maturing Phase
Merck & Co., Inc. is a global healthcare leader with two core divisions, Pharmaceuticals and Animal Health, spanning oncology, vaccines, acute hospital care, immunology, neuroscience, virology, cardiovascular and diabetes, and it employs roughly 74,000 people under CEO Robert Davis. The business quality is medium: TTM gross margin of 75.4% and TTM operating margin of 16.7% reflect a genuinely high-margin branded-drug portfolio, but TTM net margin of just 4.8% and a trailing P/E of 114.66 show how heavily acquisition charges and earnings volatility are weighing on reported profitability. Revenue grew 5.1% year over year in the most recent quarter, while earnings declined 130.2% year over year in that same quarter, and the prior material risks flag Q2 2026 GAAP EPS of negative $0.54 and non-GAAP EPS of negative $0.13, largely from a $5.7 billion Terns acquisition charge. KEYTRUDA and KEYTRUDA QLEX contributed $8.366 billion in Q2 2026, roughly half of company sales, so the equity is effectively a concentrated oncology bet with a December 2028 biosimilar cliff on the horizon. At $147.17, the shares trade at 5.47 times sales, 22.65 times free cash flow and 29.65 times EV/EBITDA, a very_expensive regime versus the company's own five-year history, and the $141.07 fair value estimate implies 4.1% downside to fair value, or a 4.3% premium to fair value. Analyst consensus is Buy with a $164.92 average target, 12.1% above the current price, so the market is pricing a successful QLEX conversion and pipeline ramp that reported earnings do not yet demonstrate. This is a good franchise at a full price with negative near-term earnings momentum, which caps the grade at C.
Merck is expensive on its own history rather than on absolute earnings power. The stock trades at 5.47 times sales, 22.65 times free cash flow and 29.65 times EV/EBITDA, and the valuation regime is classified as very_expensive relative to the past five years. The trailing P/E of 114.66 is distorted by depressed GAAP earnings, including the $5.7 billion Terns acquisition charge that drove Q2 2026 GAAP EPS to negative $0.54 and non-GAAP EPS to negative $0.13, so the multiple is not a clean read on normalized profitability. Free cash flow of $6.50 per share against a $147.17 price is the more meaningful anchor, and it still leaves the shares at a premium to the $141.07 fair value estimate, a 4.1% downside to fair value and a 4.3% premium to fair value. The gap between the $164.92 analyst average target, 12.1% above the current price, and the fair value estimate reflects the market paying today for a KEYTRUDA QLEX conversion, WINREVAIR growth and pipeline optionality that have not yet shown up in reported earnings. With revenue up only 5.1% year over year in the most recent quarter and earnings down 130.2% year over year in that quarter, the multiple is a bet on 2027 and beyond rather than on current fundamentals.
12–18 Month Outlook
In 18 months Merck will be judged on whether KEYTRUDA QLEX conversion and WINREVAIR growth can offset a shrinking mature-product base while the Terns and Cidara charges roll out of the comparison. The setup is not clean: revenue grew only 5.1% year over year in the most recent quarter, earnings fell 130.2% year over year in that quarter, TTM net margin is just 4.8%, and the shares already sit at a 4.3% premium to the $141.07 fair value estimate in a very_expensive regime versus five-year history. The realistic path is a 2027 earnings recovery as acquisition charges annualize, with the $164.92 analyst target, 12.1% above the current price, representing the optimistic case rather than the base case. The key swing factors are QLEX conversion economics, WINREVAIR adoption, Gardasil demand stabilization, and how much of the December 2028 KEYTRUDA biosimilar cliff the market begins to discount. If pipeline data disappoint or Gardasil erosion accelerates, the downside to fair value is real rather than theoretical.
Bull vs Bear
Bull Case
KEYTRUDA and KEYTRUDA QLEX generated $8.366 billion in Q2 2026, roughly half of company sales, giving Merck a dominant oncology franchise with a subcutaneous conversion path that can extend the franchise's commercial life.
TTM gross margin of 75.4% and TTM operating margin of 16.7% show the underlying branded-pharmaceutical economics remain strong despite the acquisition charges depressing net income.
Free cash flow of $6.50 per share supports a P/FCF of 22.65, and Merck continues to deploy capital into bolt-on acquisitions such as Cidara at roughly $9.2 billion, Terns at $6.8 billion including equity-award settlement, and TARGAN at about $650 million.
Analyst consensus is Buy with a $164.92 average target, 12.1% above the current $147.17 price, indicating the sell side expects the earnings trough to pass.
Revenue grew 5.1% year over year in the most recent quarter, showing the top line is still expanding even as reported earnings absorb one-time deal costs.
Bear Case
Earnings declined 130.2% year over year in the most recent quarter, with Q2 2026 GAAP EPS of negative $0.54 and non-GAAP EPS of negative $0.13, primarily reflecting a $5.7 billion Terns acquisition charge.
KEYTRUDA and KEYTRUDA QLEX contributed $8.366 billion in Q2 2026, roughly half of company sales, leaving Merck highly exposed to PD-1/PD-L1 competition and potential biosimilar competition beginning in December 2028.
The shares trade at a very_expensive valuation regime versus five-year history, with a $141.07 fair value estimate implying 4.1% downside to fair value and a 4.3% premium to fair value.
Cash and investments fell to $8.363 billion and debt-to-total-capital rose to 41.5% at June 30, 2026 after the Cidara, Terns and TARGAN transactions, reducing balance-sheet flexibility.
Mature products are eroding: Gardasil and Gardasil 9 sales fell 9% in the first half of 2026, VAXNEUVANCE revenue declined 35% and Lagevrio declined 95% in Q2, Bridion lost U.S. exclusivity in July 2026, Dificid faces U.S. generics and Lynparza received a further Paragraph IV notice.
Leadership & Competitive Position
Robert Davis
Beats guidance75% of qtrs
Capital allocationFair
Robert Davis is identified as CEO in the current company data. The visible capital-allocation record is aggressive M&A: Cidara at approximately $9.2 billion transaction value, Terns at $6.8 billion including equity-award settlement, and TARGAN at about $650 million, which pushed cash and investments down to $8.363 billion and debt-to-total-capital up to 41.5% at June 30, 2026. Those deals have not yet translated into reported earnings, with earnings down 130.2% year over year in the most recent quarter. Tenure and insider ownership are not disclosed in the current research, so no tenure figure or ownership percentage is asserted.
Competitive Moat
narrowing
intangible assetsswitching costs
KEYTRUDA and KEYTRUDA QLEX contributed $8.366 billion in Q2 2026, roughly half of company sales, which is the clearest evidence of Merck's oncology share position. That concentration is also the vulnerability: competition in PD-1/PD-L1 therapies and potential biosimilar competition beginning in December 2028 could pressure market share and pricing. On the vaccine side, Gardasil and Gardasil 9 sales fell 9% in the first half of 2026 and VAXNEUVANCE revenue declined 35% in Q2, indicating share and demand pressure in parts of the vaccine portfolio.
Disruption: Medium. The branded-pharmaceutical model is protected by patents and clinical data, but PD-1/PD-L1 competition and potential KEYTRUDA biosimilar competition beginning in December 2028 represent a defined long-dated threat, and generic entry has already hit Bridion, Dificid and Lynparza.
QuantHub Research
Valuation
Multiple
Current
Median 3yr
Median 5yr
Min 5yr
Max 5yr
P/E
114.66x
14.72x
14.78x
14.42x
19.36x
P/S
5.47x
4.06x
4.06x
3.93x
4.74x
P/FCF
22.65x
21.31x
20.07x
13.92x
30.37x
P/S 5.47x vs 5yr range 3.93-4.74x (P25=3.93x, median=4.06x, P75=4.62x)
Price Outlook (5-Year)
Bear
$113
-5.4%/yr
Base
$141
-1.1%/yr
fair value
Bull
$169
2.6%/yr
Bear/Base/Bull anchored to QuantHub fair value estimate. Base = headline fair value; Bear −20%; Bull +20%.
Earnings declined 130.2% year over year in the most recent quarter. Q2 2026 GAAP EPS was negative $0.54 and non-GAAP EPS was negative $0.13, primarily reflecting a $5.7 billion Terns acquisition charge.
KEYTRUDA concentration and oncology competition
high
KEYTRUDA and KEYTRUDA QLEX contributed $8.366 billion in Q2 2026, roughly half of company sales. Competition in PD-1/PD-L1 therapies and potential biosimilar competition beginning in December 2028 could pressure market share and pricing.
Acquisition integration and balance-sheet risk
medium
Merck completed the Cidara acquisition at approximately $9.2 billion transaction value, acquired Terns for $6.8 billion including equity-award settlement, and acquired TARGAN for about $650 million. Cash and investments fell to $8.363 billion and debt-to-total-capital rose to 41.5% at June 30, 2026.
Regulatory, reimbursement and pricing pressure
medium
Drug-pricing pressure, regulatory scrutiny, potential tariff effects and reimbursement uncertainty could affect profitability and adoption of newer products, including LIPFENDRA and oncology pipeline assets.
Gardasil and mature-product erosion
medium
Gardasil and Gardasil 9 sales fell 9% in the first half of 2026, while VAXNEUVANCE revenue declined 35% and Lagevrio declined 95% in Q2. Bridion lost U.S. exclusivity in July 2026, Dificid faces U.S. generics and Lynparza has received a further Paragraph IV notice.
Litigation and product-liability exposure
medium
Merck faces Gardasil product-liability litigation. Management does not currently expect pending legal matters to be material, but litigation outcomes and associated costs cannot be assured.
Valuation and multiple compression risk
medium
The shares trade in a very_expensive regime versus five-year history at 5.47 times sales, 22.65 times free cash flow and 29.65 times EV/EBITDA, with the $141.07 fair value estimate implying 4.1% downside to fair value and a 4.3% premium to fair value. A failure to deliver the earnings recovery implied by the $164.92 analyst target would leave the multiple exposed.
Growth Engines
KEYTRUDA QLEX conversionscaling
KEYTRUDA and KEYTRUDA QLEX together produced $8.366 billion in Q2 2026, roughly half of company sales, and the subcutaneous conversion is the primary lever to defend that oncology revenue base.
WINREVAIR cardiopulmonary franchisescaling
WINREVAIR growth is called out as a key item to watch in the third-quarter 2026 earnings release, positioning it as one of the newer non-oncology growth drivers.
Oncology pipeline and ADCsearly
Antibody-drug conjugate programs and other pipeline assets are the focus of the scheduled oncology investor event, where Merck is expected to clarify their commercial and clinical trajectory.
Acquired asset portfolioearly
Cidara at approximately $9.2 billion, Terns at $6.8 billion including equity-award settlement, and TARGAN at about $650 million add pipeline and commercial assets, though the Terns charge is the main reason earnings fell 130.2% year over year in the most recent quarter.
Merck shares close at $147.17, up 1.56% on the session
The close anchors the current valuation: 5.47 times sales, 22.65 times free cash flow, 29.65 times EV/EBITDA, and a 4.3% premium to the $141.07 fair value estimate.
2026-09-17
Merck gains as KEYTRUDA space research seeks a new home
Coverage highlights continued scientific and commercial development around the KEYTRUDA franchise, which produced $8.366 billion of Q2 2026 revenue alongside KEYTRUDA QLEX.
2026-09-16
Commentary argues Merck should buy Moderna
External speculation about large-scale M&A follows a period in which Merck already spent roughly $9.2 billion on Cidara, $6.8 billion on Terns including equity-award settlement, and about $650 million on TARGAN, leaving cash and investments at $8.363 billion and debt-to-total-capital at 41.5% at June 30, 2026.
This is AI-powered fundamental analysis built from scratch — not aggregated analyst ratings. Get this research for your entire portfolio plus daily briefings, research signals, and options income.
QuantHub research is focused on quality businesses with durable competitive advantages — companies we'd want to own for 3–5 years or more. We are not short-term traders. Every analysis is built around a single question: is this a great business available at a reasonable price for a long-term investor?
We start where most analysts finish: the fundamentals. For every company, our AI ingests years of financial statements — revenue, margins, free cash flow, and how the business has been valued by the market across multiple cycles. But numbers alone don't tell you whether a business is worth owning.
The harder work is qualitative. We assess the competitive moat: is it widening or eroding? We read the leadership track record — how capital has been allocated, whether management has earned trust through consistent execution. We look at what the market is afraid of, and whether that fear is priced in fairly or irrationally.
Valuation is always relative. A stock is cheap or expensive compared to its own history. We build scenario matrices anchored to 5-year historical multiples, then ask: what has to go right for the upside case, and what's the floor if it doesn't?
Finally, we write an 18-month forward outlook — not a price target, but a mental model of where this business will be and what the narrative will look like. Every note is dated and versioned. When material facts change, we update the thesis.
Frequently Asked Questions
Is MRK undervalued?
MRK is currently fairly valued at $148.74 vs. our fair value estimate of $141.07 (-5% upside).
What is MRK's fair value?
QuantHub Research estimates MRK's fair value at $141.07 based on our proprietary valuation model incorporating historical P/S, P/E, and P/FCF multiples over a 5-year range.
What are the key risks for MRK?
Earnings volatility: Earnings declined 130.2% year over year in the most recent quarter. Q2 2026 GAAP EPS was negative $0.54 and non-GAAP EPS was negative $0.13, primarily reflecting a $5.7 billion Terns acquisition charge. KEYTRUDA concentration and oncology competition: KEYTRUDA and KEYTRUDA QLEX contributed $8.366 billion in Q2 2026, roughly half of company sales. Competition in PD-1/PD-L1 therapies and potential biosimilar competition beginning in December 2028 could pressure market share and pricing. Acquisition integration and balance-sheet risk: Merck completed the Cidara acquisition at approximately $9.2 billion transaction value, acquired Terns for $6.8 billion including equity-award settlement, and acquired TARGAN for about $650 million. Cash and investments fell to $8.363 billion and debt-to-total-capital rose to 41.5% at June 30, 2026.
What is the bull case for MRK?
KEYTRUDA and KEYTRUDA QLEX generated $8.366 billion in Q2 2026, roughly half of company sales, giving Merck a dominant oncology franchise with a subcutaneous conversion path that can extend the franchise's commercial life. TTM gross margin of 75.4% and TTM operating margin of 16.7% show the underlying branded-pharmaceutical economics remain strong despite the acquisition charges depressing net income. Free cash flow of $6.50 per share supports a P/FCF of 22.65, and Merck continues to deploy capi
How confident is QuantHub in MRK?
QuantHub has moderate conviction in MRK. Research last updated 2026-09-18.